EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CXCL10 drives pancreatic ductal adenocarcinoma progression through CXCR3-ERK/MAPK signaling

Haomin Yuan, Longhang Wu, Yu Song, Hongqin Lin, Fengchun Lu

Cellular Signalling · 2026-10 · 146 · 112637

DOI: 10.1016/j.cellsig.2026.112637 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2026-10. Verfasst von Haomin Yuan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Union Hospital of Fujian Medical University, Fuzhou 350001, Fujian, China. Hauptthemen laut MEDLINE: Receptors, CXCR3, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Chemokine CXCL10. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Clinical Specialty Discipline Construction Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The functional significance of the CXCL10/CXCR3 chemokine axis in pancreatic ductal adenocarcinoma (PDAC) remains incompletely defined. Through integrated analysis of clinical datasets, patient samples, and functional assays, we demonstrate that CXCL10 and CXCR3 are frequently overexpressed in PDAC, with high levels correlating with advanced disease and poorer overall survival. Notably, CXCR3 expression emerged as an independent prognostic indicator. Functionally, CXCL10 treatment or overexpression enhanced PDAC cell proliferation, migration, invasion, clonogenicity, and epithelial-mesenchymal transition (EMT). Conversely, CXCL10 knockdown or pharmacological CXCR3 inhibition with AMG487 suppressed these oncogenic phenotypes. Mechanistically, CXCL10 signaling activated the ERK/MAPK pathway, and ERK inhibition abolished its tumor-promoting effects. This study establishes that CXCL10 drives PDAC progression through CXCR3-dependent ERK/MAPK activation, positioning this axis as a potential therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, CXCR3Carcinoma, Pancreatic DuctalPancreatic NeoplasmsChemokine CXCL10MAP Kinase Signaling SystemHumansCell Line, TumorCell ProliferationDisease ProgressionCell MovementAnimalsEpithelial-Mesenchymal Transition

Stichwörter der Autor:innen

CXCL10CXCR3ERK/MAPK signalingPDACTumor progression

Substanzen

Receptors, CXCR3Chemokine CXCL10CXCR3 protein, humanCXCL10 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, Union Hospital of Fujian Medical University, Fuzhou 350001, Fujian, China.
  • Department of Laboratory Medicine, Provincial Hospital of Fuzhou University, Fuzhou 350001, Fujian, China.
  • Department of General Surgery, Union Hospital of Fujian Medical University, Fuzhou 350001, Fujian, China. Electronic address: fengchun160@fjmu.com.

Förderung

  • National Key Clinical Specialty Discipline Construction Program of China

Zitieren

APA

Yuan, H., Wu, L., Song, Y., Lin, H., & Lu, F. (2026). CXCL10 drives pancreatic ductal adenocarcinoma progression through CXCR3-ERK/MAPK signaling. Cellular Signalling, 146, 112637. https://doi.org/10.1016/j.cellsig.2026.112637

Vancouver

Yuan H, Wu L, Song Y, Lin H, Lu F. CXCL10 drives pancreatic ductal adenocarcinoma progression through CXCR3-ERK/MAPK signaling. Cellular Signalling. 2026;146:112637. doi:10.1016/j.cellsig.2026.112637

BibTeX
@article{Yuan2026,
  author = {Yuan, Haomin and Wu, Longhang and Song, Yu and Lin, Hongqin and Lu, Fengchun},
  title = {CXCL10 drives pancreatic ductal adenocarcinoma progression through CXCR3-ERK/MAPK signaling},
  journal = {Cellular Signalling},
  year = {2026},
  volume = {146},
  pages = {112637},
  doi = {10.1016/j.cellsig.2026.112637}
}
Kostenlos starten →